# iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer

> **NCT03867799** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Royal Marsden NHS Foundation Trust** · enrollment: 25 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03867799
- **Lead sponsor:** Royal Marsden NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-03-27
- **Primary completion:** 2022-10-21
- **Final completion:** 2024-09
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2024-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03867799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03867799, "iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03867799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*